Access the full article to explore five investigator-informed trends shaping obesity and metabolic trial planning
Surgical outcomes in patients with preoperative GLP-1 therapy: A retrospective analysis
Ideal candidates are individuals seeking to eliminate persistent fat in specific body areas where neither diet or exercise has proven effective
Attitudes toward weight and medications Americans views of weight and related drugs appear to be nuanced
2 1 JDMM BMI200320152015BMI25BMI22 303402 GLP-12GLP-1GLP-1 GLP-1111GLP-1 GLP-1 GLP-12 GLP-1 GLP-1 2GLP-1 GLP-1 210GLP-14GLP-1 GLP-1 2393GLP-14 GLP-1GLP-1DPP-4 :LiraglutideDPP-42 3827(5,032)129(2,091)24HbA1cHbA1c 0.9mg:LiraglutideDPP-4(:Vildagliptin:Sitagliptin:Linagliptin:Alogliptin:Teneligliptin:Trelagliptin:Omarigliptin) 2:Liraglutide0.9mgDPP-4 1HbA1c7% GLP-1HbA1c1HbA1c7.0%CCPI,100C/HbA1c7.0%SU1.861.10 GLP-1 GLP-1 GLP-1GLP-1GLP-1 BMI 25kg/m257 150mg/dL2200mg/dL0.3mg/10.3mg/0.9mg/ GLP-1 GLP-12 GLP-1212GLP-1371.59kg GLP-1 GLP-1 GLP-1LEADERSUSTAIN-6 24 24 14GLP-1DPP4GLP-1GLP-1GLP-1 GLP-14 2 SU10 UKPDS24,209 SU2,729met3421,13810 Holman RR et al.N Engl J Med 359(15)1577-1589, 2008 21013159242 50% GLP-130 GLP-1 23HbA1c7%1,168 HbA1c7%6Hb1Ac7% Pantalone KM, et al
Gillett MB, Suko JR, Santoso FO, Yancey PH